Status:
RECRUITING
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Lead Sponsor:
Dr. Inge Winter
Collaborating Sponsors:
Universität Münster
Conditions:
Major Depressive Disorder
Treatment Resistant Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically sig...
Detailed Description
Rationale Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clin...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- In- or outpatients, at least 18 years of age up until 65.
- Being willing and able to provide written informed consent. Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure.
- Female subjects of child bearing potential must use effective contraception during the trial as per the requirements of the applicable SmPCs and should have a negative pregnancy test at visit 1 or 2 (before randomisation).
- Meeting diagnostic criteria for a primary diagnosis of major depressive disorder (without psychotic features), according to DSM-5. The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2).
- Subject experiences a treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3; perferably, this treatment is a first-line pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs).
- Subject and clinician intend to change pharmacotherapeutic treatment. However, other lines of treatment are allowed as well.
- A minimum symptom severity threshold needs to be present (moderate level; see below) and subject needs to experience functional impairment.
- The minimum symptom severity threshold is a score of ≥20 on the Montgomery Åsberg Depression Rating Scale (MADRS)
- Functional impairment is defined as a score of 5 or higher on any of the three scales of the Sheehan Disability Scale (SDS).
- Exclusion criteria:
- Being pregnant or breastfeeding.
- Subject has used (es)ketamine previously for the treatment of depressive symptoms.
- Subject has a known intolerance to (es)ketamine or to all TAU medication.
- Meeting any of the contraindications for (es)ketamine, or to all TAU medication options, as specified within the applicable SmPC, supported by clinically significant abnormal values on local laboratory tests, electrocardiogram (ECG) or physical examinations.
- Subject has participated in another clinical trial in which the subject received an experimental or investigational drug or agent within 30 days before visit 1.
- Subject experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the trial, or may influence the result of the trial, or the subject's ability to participate in the trial.
- Subjects with active suicidal ideation with some intent to act, without specific plan ("Yes" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent ("Yes" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study
- Subject meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed.
- Subjects have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- Subjects dependent on the sponsor, investigator or trial site must be excluded from participation in advance.
Exclusion
Key Trial Info
Start Date :
August 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2028
Estimated Enrollment :
418 Patients enrolled
Trial Details
Trial ID
NCT05973851
Start Date
August 31 2024
End Date
June 30 2028
Last Update
September 26 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Innsbruck
Innsbruck, Austria
2
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld
Bielefeld, Germany
3
LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft
Dortmund, Germany, 44287
4
University Hospital Frankfurt am Main - Goethe University
Frankfurt am Main, Germany